The global intravenous immunoglobulin market size was valued at USD 14.81 billion in 2025 and is projected to grow from USD 15.89 billion in 2026 to USD 27.92 billion by 2034, registering a CAGR of 7.3% during the forecast period from 2026 to 2034. North America dominated the intravenous immunoglobulin market with a market share of 43.25% in 2025.
The antibodies produced by the immune system naturally to help fight disease and infection are known as immunoglobulins. IVIG, also known as intravenous immunoglobulin, is a treatment that combines immunoglobulins donated by various individuals to treat a variety of conditions. It is administered intravenously or through a drip. Plasma is used to create IVIG and other immunoglobulins. IVIG is used to lessen the effects of some inflammatory immune-system-related diseases, also referred to as autoimmune diseases. Additionally, it is used to raise immunoglobulin levels that are low or that have fallen because of taking other medications, like rituximab.
Download a Free Sample To learn more about this report,
New IVIG Products Are Broadening Treatment Choice
The Intravenous Immunoglobulin Market is seeing continued product development and regulatory approvals, giving healthcare systems more options for replacement therapy. IVIG is produced from donated human plasma and provides concentrated immunoglobulin G antibodies. New approvals matter because manufacturing is technically demanding and the market depends on a limited number of plasma fractionation networks. Additional products can diversify supply while increasing competition around purity, concentration, manufacturing consistency, packaging, and clinical evidence. Regulatory activity also shows that primary immunodeficiency remains an important commercial application. As more suppliers obtain approvals in major markets, hospitals and immunology centers gain additional treatment options while manufacturers expand their geographic reach and production requirements.
In September 2025, the U.S. FDA approved Kedrion's QIVIGY, a 10% intravenous human immunoglobulin solution for treating adults with primary humoral immunodeficiency.
Expanding Use in Immune and Neurological Disorders Supports Demand
IVIG demand is supported by its use across several immune and neurological conditions. Products such as PRIVIGEN are indicated for primary humoral immunodeficiency, chronic immune thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy in specified patient groups. This creates recurring demand because some patients require continuing replacement or immunomodulatory therapy rather than a single treatment. The commercial effect extends beyond immunology into neurology and hematology, allowing manufacturers to serve several specialist-care settings through the same plasma-derived product platform. Continued regulatory activity around established IVIG products also requires manufacturers to maintain clinical evidence, pharmacovigilance, production capacity, and dependable distribution as treatment populations and approved uses evolve.
In May 2025, the FDA approved updated labeling for CSL Behring's PRIVIGEN, an IVIG product used for primary immunodeficiency, chronic ITP, and adult CIDP.
Dependence on Donated Plasma Restricts Supply Flexibility
Limited plasma availability is a structural restraint because immunoglobulin production cannot be expanded as quickly as conventional pharmaceutical manufacturing. Plasma must be collected from eligible donors, tested, pooled, fractionated, purified, and processed under strict quality requirements. WHO reports that only 49 of 168 reporting countries manufacture plasma-derived medicinal products using plasma collected domestically, while 119 reported relying completely on imports or not using these products during the reporting period. This concentration increases dependence on international collection and manufacturing networks. When demand rises faster than plasma collection or fractionation capacity, hospitals can face supply pressure, making plasma availability a fundamental constraint on IVIG market expansion.
In September 2025, EMA reported continuing shortages of human normal immunoglobulins across several EU countries, partly caused by an unexpected increase in demand, with disruption expected through June 2026.
Geographic Expansion Can Improve Access to Established IVIG Therapies
Geographic expansion provides an important opportunity because access to plasma-derived medicines remains uneven between countries. Manufacturers with established IVIG products can grow by obtaining additional national registrations, strengthening distribution networks, and supporting healthcare systems where immunoglobulin availability is limited. This approach can be especially valuable because developing a completely new plasma-derived medicine requires considerable clinical and manufacturing investment, while extending an established product into additional countries can broaden access using an existing production platform. WHO also encourages countries to develop sustainable blood and plasma programs to improve equitable access to immunoglobulins and other plasma-derived medicines, creating opportunities across collection, fractionation, distribution, and finished-product supply.
In 2025, CSL reported new PRIVIGEN registrations in Bahrain and Oman, together with new indications in Argentina and the Dominican Republic, extending the product's international reach.
Safety Surveillance and Batch Consistency Remain Critical
Maintaining consistent safety across plasma-derived immunoglobulin lots is a major market challenge. IVIG is produced from biological starting material collected from many donors, so manufacturers need rigorous donor screening, purification, manufacturing controls, batch testing, traceability, and post-market surveillance. Even after regulatory approval, safety signals can require investigation, communication with healthcare professionals, or withdrawal of affected lots. These responsibilities increase quality-control costs and make manufacturing consistency central to brand reputation and supply continuity. The challenge is especially important because patients receiving immunoglobulin may require repeated treatment. Manufacturers therefore need to combine expanding production with strict pharmacovigilance and rapid investigation of unusual adverse-event patterns.
In October 2025, the FDA investigated increased reports of allergic and hypersensitivity reactions associated with certain IVIG and subcutaneous immunoglobulin lots after voluntary lot withdrawals had begun in March.
Myasthenia Gravis is Projected to Register the Fastest Growth at a CAGR of 8.35%
The myasthenia gravis segment is projected to register the fastest growth in the intravenous immunoglobulin market at a CAGR of 8.35% during the forecast period, driven by increasing utilization of IVIG for managing severe symptoms and acute exacerbations of the autoimmune neuromuscular disorder. Intravenous immunoglobulin helps modulate abnormal immune responses and can provide relatively rapid improvement in muscle weakness among selected patients. Increasing diagnosis of autoimmune neurological disorders, expanding access to immunomodulatory therapies, and growing awareness of effective treatment approaches continue to support demand for IVIG in myasthenia gravis management.
Request Customizationto receive a tailored report.
Hospital Pharmacy Dominated the Market with 68.4% Share in 2025
The hospital pharmacy segment accounted for the largest share of the global intravenous immunoglobulin market at 68.4% in 2025, supported by the extensive administration of IVIG therapies in hospitals under professional medical supervision. Intravenous immunoglobulin is commonly used for treating immune deficiencies, autoimmune diseases, and neurological disorders that may require controlled dosing and patient monitoring. Hospitals also manage patients with severe and complex conditions requiring immediate access to immunoglobulin therapies. Growing treatment volumes, expanding hospital infrastructure, and increasing availability of specialized infusion services continue to reinforce the segment's dominant market position.
Speak to an Analystto discuss market opportunities.
North America dominated the intravenous immunoglobulin market with the largest 43.25% market share in 2025, representing a market value of USD 6.41 billion. The region is projected to grow at a CAGR of 7.18% during the forecast period. Its leadership is supported by advanced healthcare infrastructure, widespread availability of immunoglobulin therapies, established plasma collection networks, and strong demand for treatments addressing immune deficiencies and autoimmune and neurological disorders. Hospitals and specialty clinics extensively utilize intravenous immunoglobulin for patients requiring antibody replacement or immunomodulatory therapy. Growing diagnosis of immune-related conditions and continued expansion of specialty treatment services are supporting consumption. Continued healthcare investment strengthens North America's position in the global intravenous immunoglobulin market.
The United States is an important contributor to the intravenous immunoglobulin market due to its advanced healthcare infrastructure, extensive plasma collection ecosystem, large network of specialty treatment centers, and strong presence of plasma-derived therapy manufacturers. Intravenous immunoglobulin is used across immunology, neurology, hematology, and other medical specialties for patients requiring antibody replacement or immunomodulatory treatment. Improving diagnosis of primary immunodeficiency disorders and growing clinical management of autoimmune and neurological diseases support therapy utilization. Hospitals, specialty clinics, and infusion centers provide established channels for treatment administration. Continued development of plasma collection, fractionation, and specialty therapeutic capabilities supports growth of the country's intravenous immunoglobulin market.
Canada contributes to the intravenous immunoglobulin market through its established healthcare system, specialized immunology and neurology services, and growing clinical requirements for plasma-derived therapies. Intravenous immunoglobulin is utilized for patients with selected immunodeficiency, autoimmune, hematological, and neurological conditions where antibody replacement or immunomodulation is required. Hospitals and specialized healthcare centers play an important role in treatment administration and patient monitoring. Increasing awareness and improved diagnosis of immune-related disorders are supporting appropriate therapy utilization. Healthcare providers are also emphasizing efficient management of immunoglobulin supplies because of the specialized plasma-based manufacturing process. Continued development of specialty care supports long-term growth of Canada's intravenous immunoglobulin market.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific is the fastest-growing region in the intravenous immunoglobulin market and is expected to expand at a CAGR of 8.63% during the forecast period. The region accounted for 20.15% of the global market in 2025, representing a market value of USD 2.98 billion. Growth is supported by improving healthcare infrastructure, increasing diagnosis of immune-related disorders, expanding access to specialty treatments, and rising healthcare expenditure. Development of hospitals and specialized treatment centers is increasing availability of immunoglobulin therapy across major markets. Growing awareness of primary immunodeficiencies and neurological conditions is further supporting clinical demand. Expansion of plasma collection and fractionation capabilities also creates opportunities, supporting strong development of the intravenous immunoglobulin market across Asia Pacific.
Japan is an important contributor to the intravenous immunoglobulin market through its sophisticated healthcare system, advanced clinical capabilities, and established treatment infrastructure for immune and neurological disorders. Intravenous immunoglobulin is used across specialized medical settings for selected conditions requiring antibody replacement or immune modulation. The country's aging population and strong emphasis on management of complex chronic diseases contribute to demand for advanced specialty therapies. Hospitals and specialist physicians benefit from sophisticated diagnostic capabilities that facilitate identification and management of immune-mediated conditions. Continued clinical research, improvements in treatment protocols, and availability of specialized healthcare services strengthen Japan's contribution to the Asia Pacific intravenous immunoglobulin market.
China plays a significant role in the intravenous immunoglobulin market due to its large patient population, expanding healthcare infrastructure, growing plasma-derived products industry, and improving access to specialized treatments. Hospitals use intravenous immunoglobulin across various immune, neurological, and hematological applications based on clinical requirements. Increasing diagnosis of immune-related diseases and expansion of tertiary healthcare facilities are supporting treatment demand. Development of domestic plasma collection and fractionation capabilities is also important for improving availability of immunoglobulin products. Continued healthcare modernization, expansion of specialty medical services, and strengthening of domestic plasma-derived therapy manufacturing reinforce China's importance within the Asia Pacific intravenous immunoglobulin market.
Europe accounted for 27.35% of the global intravenous immunoglobulin market in 2025, reaching a market value of USD 4.05 billion. The region is anticipated to grow at a CAGR of 6.94% during the forecast period. Market development is supported by established healthcare systems, strong awareness of immunodeficiency disorders, specialized neurological care, and widespread availability of plasma-derived therapies. Intravenous immunoglobulin is used across hospitals and specialist treatment centers for multiple approved clinical applications requiring antibody replacement or immunomodulatory effects. Established plasma collection and fractionation capabilities contribute to regional product availability. Growing attention to early diagnosis and effective management of immune-mediated conditions further supports expansion of the intravenous immunoglobulin market across Europe.
Germany is an important contributor to the intravenous immunoglobulin market in Europe due to its advanced healthcare infrastructure, strong pharmaceutical industry, established plasma collection capabilities, and specialized clinical services. Hospitals and specialty centers utilize immunoglobulin therapies across immunology, neurology, hematology, and other treatment areas. Advanced diagnostic capabilities support identification of patients with primary immunodeficiencies and immune-mediated diseases that may require immunoglobulin therapy. Germany's strong life sciences ecosystem also supports plasma processing, pharmaceutical manufacturing, clinical research, and development of specialty biological therapies. Continued investment in healthcare services and management of complex immune disorders strengthens Germany's position within the European intravenous immunoglobulin market.
The United Kingdom contributes to the intravenous immunoglobulin market through its established healthcare system, specialist immunology and neurology services, clinical research capabilities, and structured use of plasma-derived therapies. Intravenous immunoglobulin is administered for selected immune deficiencies and autoimmune, neurological, and hematological conditions according to clinical requirements. Specialist healthcare professionals play an important role in patient assessment, treatment selection, administration, and monitoring. Growing understanding of rare immune disorders and improvements in diagnostic capabilities are supporting appropriate identification of patients who may benefit from treatment. Continued development of specialist medical services and evidence-based therapeutic practices supports the United Kingdom's contribution to the European intravenous immunoglobulin market.
Latin America represented 5.45% of the global intravenous immunoglobulin market in 2025, with a market value of USD 0.81 billion. The region is expected to register a CAGR of 7.56% during the forecast period. Growth is supported by improving healthcare infrastructure, increasing access to specialty medicines, growing awareness of immune-related diseases, and expansion of diagnostic capabilities. Hospitals and specialized treatment centers are increasing access to immunoglobulin therapies for patients requiring antibody replacement and immunomodulatory treatment. Improvements in healthcare coverage and development of specialty care services are further supporting demand. Increasing availability of advanced biological therapies and continued healthcare modernization support expansion of the intravenous immunoglobulin market across Latin America.
Brazil is an important contributor to the intravenous immunoglobulin market in Latin America due to its large healthcare system, substantial patient population, growing specialty care infrastructure, and increasing demand for plasma-derived therapies. Hospitals and specialized centers use intravenous immunoglobulin for selected immunological, neurological, and hematological disorders. Increasing physician awareness and improvements in diagnosis of primary immunodeficiencies and immune-mediated conditions are supporting appropriate treatment adoption. Expansion of specialized healthcare facilities is also improving access to complex biological therapies. Development of plasma-related healthcare capabilities and continued investment in specialty medicine reinforce Brazil's importance within the regional intravenous immunoglobulin market.
The Middle East and Africa accounted for 3.8% of the global intravenous immunoglobulin market in 2025, representing a market value of USD 0.56 billion. The region is projected to expand at a CAGR of 6.88% during the forecast period. Market development is supported by improving healthcare infrastructure, expansion of specialty hospitals, growing awareness of immunodeficiency disorders, and increasing availability of advanced biological therapies. Development of diagnostic services is helping healthcare professionals identify patients requiring specialized immune therapies. Investment in modern hospitals and specialty treatment capabilities is also improving access to intravenous immunoglobulin across major healthcare markets. These factors support long-term development of the intravenous immunoglobulin market across the region.
The UAE contributes to the intravenous immunoglobulin market within the Middle East and Africa through its modern healthcare infrastructure, specialized hospitals, advanced diagnostic capabilities, and increasing availability of complex biological therapies. Specialist centers provide treatment for immune, neurological, and hematological conditions that may require immunoglobulin therapy based on individual clinical needs. Development of sophisticated healthcare facilities and recruitment of specialized medical professionals are improving diagnosis and management of complex immune-mediated disorders. The country's strong pharmaceutical distribution infrastructure also supports access to specialized plasma-derived products. Continued investment in advanced healthcare services and specialty medicine strengthens the UAE's role in the regional intravenous immunoglobulin market.
The intravenous immunoglobulin market is moderately concentrated, with major companies such as CSL Behring, Grifols, Takeda Pharmaceutical, Octapharma, Kedrion Biopharma, Biotest, LFB Biotechnologies, ADMA Biologics, and Prothya Biosolutions competing through plasma collection networks, manufacturing capacity, product portfolios, and regulatory approvals. Competition is increasingly driven by reliable plasma supply, expansion of fractionation capacity, new therapeutic indications, and improved immunoglobulin formulations. Vertically integrated companies benefit from controlling plasma collection through manufacturing and distribution, while leading participants continue investing in capacity expansion and clinical development to meet growing demand for plasma-derived therapies.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ on Chip Market Size, Share, Growth, Analysis, 2034
3D Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
Cancer Biologics Market Size, Share, Growth, Forecast, 2034
North America Tangential Flow Filtration Market Size, Share and Forecast to 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
Antimicrobial Peptides Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com